We are a pioneer in developing novel therapeutics aimed
at treating neurological and neuropsychiatric brain disorders.



GliaCure has closed its Seed C Financing Round

GliaCure has successfully closed it’s Seed C financing round, GliaCure has raised over $11 million to date from private investors and charitable foundations such as ADDF . GliaCure will be presenting at the NeuroTech Investing and Partnering Conference on May 21, 2019 in Boston, Massachusetts.



GliaCure Highlighted in ADDF Annual Report

GliaCure’s compound GC021109 and its successful Phase 1 clinical trial were highlighted in the Alzheimer’s Drug Discovery Foundation (ADDF) Annual Report, issued in late 2017. The report points out that there is growing research to suggest that anti-inflammatory approaches may hold the key to treating the underlying causes of Alzheimer’s disease, and shows that GC021109…more »



Support for the Amyloid Theory and Potential Preventative Treatment

The GliaCure team was excited by a recent study out of the University of Finland. Led by Mikko Hiltunen, the group provided support for the hypothesis that amyloid beta (Aβ) plays a key role in the pathology of Alzheimer’s disease. Five years ago an Icelandic team discovered that a mutation in the amyloid precursor protein…more »



Haydon Lab Discovers Role of Astrocytes in Schizophrenia

On May 4, 2017 GliaCure President Philip Haydon’s laboratory at Tufts University published its findings on the role of astrocytes in schizophrenia in the journal Neuron. N-methyl D-aspartate receptors (NMDARs) play a direct role in many aspects of brain physiology. It is hypothesized that diminished functioning of synaptic NMDAR signaling underlies the etiology of schizophrenia.…more »



Prevention, Not Cure, as a Way Forward in Alzheimer’s Disease

Many of us have read with dismay of recent clinical trial failures in Alzheimer’s disease. Are researchers and pharma companies wrong in considering amyloid as a target for therapies? Not necessarily. As a recent cover article in Newsweek points out, the problem with many of these trials may not be the target but the point…more »



GliaCure Highlighted in ADDF Top 5 Advances Report

The Alzheimer’s Drug Discovery Foundation (ADDF) recently reported on the top five Alzheimer’s research advances of 2016. Among these advances was the increasing evidence supporting a key role for neuroinflammation in the progress of Alzheimer’s disease. The article specifically referenced GliaCure’s Phase 1 trial in mild to moderate Alzheimer’s patients using GC021109, which targets inflammation.…more »



Phil Haydon’s Alzheimer’s Research Featured in Tufts Now

GliaCure President Phil Haydon’s research on Alzheimer’s disease is featured in Tufts Now, the online content and information hub for the university community. The article, authored by Bruce Morgan, details the initial resistance by the scientific community to the hypothesis that glia play an active role in brain signaling, Phil’s first discoveries regarding the role…more »



GliaCure Completes Successful Proof of Concept Phase 1b Clinical Trial in Alzheimer’s Disease

GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced yesterday that it has successfully completed a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a disease-modifying treatment for Alzheimer’s disease. The trial, which began in February 2015,…more »



GliaCure President presents at ADDF, Society for Neuroscience conferences

On October 6 GliaCure President Phil Haydon presented an invited talk at the ADDF’s 16th International Conference on Alzheimer’s Drug Discovery in New Jersey. In his presentation, titled, “The P2Y6 receptor as a therapeutic target for Alzheimer’s disease”, Phil outlined the strategy underlying the company’s approach to development of a therapy to halt disease progression…more »



Mixed results in Alzheimer’s trials but continued enthusiasm for the amyloid hypothesis and the development of treatments

At the Alzheimer’s Association International Conference (AAIC) this week in Washington DC, Biogen and Eli Lilly presented results from their latest Alzheimer’s disease clinical trials. Biogen caused a great deal of excitement earlier this year when they released data from a Phase 1b clinical trial using an antibody to remove amyloid from the brain (see…more »

Page 1 of 6